Alembic Pharmaceuticals Limited · NSE:APLLTD
Alembic Pharmaceuticals — Investor Presentation (July 2018)
15 slides from Alembic Pharmaceuticals's investor presentation, July 2018
Slide 1: Alembic Pharmaceuticals Ltd Investor Presentation
Alembic Pharmaceuticals Ltd Investor Presentation July-2018
Slide 2: Contents
Contents 1. Milestones 2. Quarterly Highlights 3. Yearly Highlights 4. Business - International - India 5. Strategy 6. Financials - Annual 7. Shareholding Pattern
Slide 3: Safe Harbor Statement
Safe Harbor Statement Materials and information provided during this presentation may contain ‘forward-looking statements’. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to diffe
Slide 4: Milestones
Milestones 1907 Established by Amin family 2006 FDA approves API facility 2007 Acquired Dabur’s Indian Cardiology, GI and Gynaecology brands 2008 FDA approves Formulation facility 2010 Pharmaceuticals business demerged from Alembic – APL listed. 2012 Rhizen JV for NCE research Launched first NDA wit
Slide 5: Highlights – Q1FY19
Highlights – Q1FY19 Financial Highlights India Formulations Gr% Rs 2.36bn Rs 3.31bn 40% Particularss ( Rs. bn) Q1 LY Q1 CY Gr% 3.50 Net Sales 6.48 8.63 33% 3.00 11% 36% EBITDA Pre R&D 1.95 2.67 37% 2.50 28% 11% Margin % 30% 31% 2.00 48% 27% R&D 0.94 1.21 29% 1.50 R&D % 15% 14% 1.00 61% EBITDA Post R
Slide 6: Highlights – FY18
Highlights –FY18 Financial Highlights India Formulations Gr% Rs 12.54bn Rs 12.74bn 2% Particular (Rs bn) FY17 FY18 Gr% 14.00 Net Sales 31.34 31.31 0% 12.00 10% 10% 6% EBITDA Pre R&D 10.36 10.27 -1% 10.00 33% 34% 8.00 5% Margin % 33% 33% 6.00 R&D 4.27 4.11 -4% 4.00 58% 56% 2.00 -1% R&D % 14% 13% ‐ EB
Slide 7: Business
Business 6.0 Key Numbers (Rs bn) Capex 4.8 3.2 31.6 31.3 31.3 10.1 6.2 6.4 3.2 4.3 4.1 FY16 FY17 FY18 Sales EBITDA R&D R&D: Manufacturing: Formulation: Vadodara , Hyderabad and USA Formulation: Oral Solids, Panelav (Mar18)* D (H1FY18) Oncology Injectables (H2FY19) General Injectables (H2FY19) API: V
Slide 8: International Formulations
International Formulations Sales (Rs bn) ANDA Filed Filings: 132 Approval: 70* CAGR 21% * Incl 9 tentative 26 14.6 12.4 12.1 20 5.6 5.9 7 8 4 FY14 FY15 FY16 FY17 FY18 FY14 FY15 FY16 FY17 FY18 R&D Spend (Rs bn) Milestones and Update 13.6 13.1 10.0 Acquired US based Orit Laboratories LLC 6.6 6.3 4.3
Slide 9: India Formulations
India Formulations Sales (Rs bn) Marketing Organisation CAGR 7% 5000 + marketing team 12.5 12.7 11.8 11.0 9.7 17 marketing divisions Added new divisions in gynaecology, cardiology , GI, urology 170 products, 15% of products in NLEM Launch 20-25 products every year FY14 FY15 FY16 FY17 FY18 Key
Slide 10: Therapy-wise Performance Q1FY19
Therapy-wise Performance Q1FY19 (Source : ORG JUN 2018)
Slide 11: Therapy-wise Performance MAT JUN 18
Therapy-wise Performance MAT JUN 18 (Source : ORG JUN 2018)
Slide 12: Strategy
Strategy R&D Pipeline Growth drivers Dosage Form FY14 FY18 R&D: Rapidly expand breadth and quality of pipeline Oral Solids Doubled internal OSD grid. injectable, dermatology ophthalmology and oncology. Expanded grid 5 fold Injectables Partnerships to gain time Oncology Build manufacturin
Slide 13: Financials – 5 years
Financials – 5 years Sales CAGR% Sales (Rs bn) CAGR 14% Rs 18.7bn Rs 31.3bn 14% 18% API 18% 21% 31.6 31.3 31.3 52% 41% India 7% 20.7 18.7 39% International 22% 30% FY14 FY18 FY14 FY15 FY16 FY17 FY18 CAGR: 15% Net Profit (Rs bn) CAGR: 14% EBITDA (Rs bn) 32% 23% 19% 19% 20% 21% 13% 14% 13% 13% Margins
Slide 14: Latest Shareholding Pattern
Latest Shareholding Pattern % of Total Shareholding 13 Promoter & Promoter group 14 FI/FII/MF Public 73 Market capitalisation (Rs bn) CAGR 14% 113 118 Total paid-up share capital 377.03mn 103 95 86 Total number of shares O/S 188.52mn No. of shareholders >50 K 54 FY14 FY15 FY16 FY17 FY18 Q1FY19
Slide 15: Thank You
THANK YOU
Alembic Pharmaceuticals — Investor Presentation (July 2018) on 6ix